ozempic hims - Search News

Hims & Hers Health, Ozempic

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared "aspirational."

Quartz on MSN · 21h

Hims & Hers can't sell off-brand Ozempic forever. But it can still sell these weight loss drugs

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, the company will soon have to halt sales of its cheaper alternative. That said,

CNBC on MSN · 1d

Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended trading.

Wall Street Journal · 1d

Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.

AOL · 1d

Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Hims & Hers Health, co and US FDA

Fortune · 2d

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Investopedia on MSN · 4d

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Eli Lilly’s Wegovy and Novo Nordisk’s Ozempic has been resolved.

Reuters · 1d

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list,

17mon MSN

Why Hims & Hers Health, Inc. (HIMS) Went Down on Tuesday

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

ConsumerAffairs22h

Hims & Hers withdraws from Wegovy, Ozempic market

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

1don MSN

Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

KTNV Las Vegas1d

Hims and Hers likely to stop selling cheaper versions of GLP-1 medications

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

24/7 Wall St1d

HIMS Stock Craters - Is It a Buying Opportunity?

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

Hims & Hers offers upbeat forecast, but stock slides after hours

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Money Morning4d

Ozempic Maker Is Ready to Fight Back Against Hims & Hers

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

24/7 Wall St. on MSN1d

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Hims & Hers Health, Ozempic

Hims & Hers Health, co and US FDA

Related topics